Navigation Links
Genes Unlock New Treatments for Deadly Melanoma
Date:10/25/2007

Scientific Meeting Highlights New Therapies and Diagnostics,

Holding Promise for Melanoma Patients

NEW YORK, Oct. 25 /PRNewswire-USNewswire/ -- Record-high registration at the upcoming 2007 International Melanoma Congress signals new promise and hope in treating a disease that has long held a dismal prognosis for those in the advanced stages. Caught early, melanoma is one of the easiest cancers to treat, but caught late, melanoma is one of the most incurable and deadly.

This year's Congress highlights the growing understanding about the underlying genetic mutations that cause melanoma. "With each genetic mutation we successfully identify, it opens up yet another door to a new therapy," says Ze'ev Ronai, Ph.D., organizer of this year's Congress and Program Director at the Burnham Institute for Medical Research. "What's clear is that a broad-spectrum approach to treating advanced melanoma is rapidly being replaced by targeted and likely personalized therapies."

The median life expectancy for those with advanced melanoma is nine months and existing therapies have not improved survival in more than a decade. Approximately five years ago, the research community began unlocking the underlying genetic malfunctions that occur in cells, causing melanoma. Today, researchers are beginning to correlate those discoveries to therapies that may have a meaningful impact on the survival of patients.

"We're starting to understand that melanoma is actually many different diseases and that there is not one easy magic bullet that we're going to find," says Lynn Schuchter, M.D., Professor of Medicine at the Abramson Cancer Center of University of Pennsylvania. "But there is great excitement not only for the drugs in development, but also from the fact that much of the basic science being done has implications for patients now. In many cases we don't have to wait for a new drug to be developed. Drugs that are already on the market are being used to slow down disease progression."

Highlights of the Congress includes:

-- research uncovering the usefulness of an existing drug

-- promising results of Stage II and Stage III clinical trials

-- a better diagnostic tool soon to be available

-- basic research findings that will serve as a platform

for future therapies.

The Society for Melanoma Research meeting also marks a change in the Society's main scientific publication. Pigment Cell Research will become Pigment Cell and Melanoma Research to underscore the rapidly expanding potential in melanoma research, and will serve as a focal point for the international research community in discussing advances in field. A preview issue produced for the Congress will be dedicated to melanoma research. The renamed journal will be officially launched in January 2008.

The Society for Melanoma Research (SMR) is an all-volunteer group of scientists working to find the mechanisms responsible for melanoma and, consequently, new therapies for this cancer. SMR contributes to advances in melanoma research by bringing together researchers in a non-competitive way to unite the scientific community. The Society has commissioned the Roadmap for Melanoma which outlines the key targets for research and therapy that need to be addressed by 2010. http://www.melanomacongress07.net

CONTACT: Berna Diehl

703-966-3602

berna@jonespa.com


'/>"/>
SOURCE The Society for Melanoma Research
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
2. Genes for lung disease
3. Genesis of SUPAC
4. Cirrhosis linked to genes
5. Altering genes through calories
6. Predictable genes
7. Genes for Vision discovered
8. Endometriosis coalesced with genes
9. Birth weight may be influenced by genes
10. New breast cancer genes discovered
11. Altitude sickness connected to genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... DC (PRWEB) , ... February 11, 2016 , ... ... an upcoming Feb. 23 webinar, “Intel’s Direct-to-Employee Benefit Model: A Case Study for ... not-for-profit Catholic health care system that’s partnering with Intel on value-based health benefits ...
(Date:2/11/2016)... ... February 11, 2016 , ... veEDIS Clinical Systems, ... with highly adaptable algorithms, has been updated to help Emergency Department physicians and ... consistent with Zikas and a travel history to affected regions, or potential exposure ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... call for nominations seeking candidates for the Board of Commissioners. Individuals interested in ... skills and experience with diversity of clinical practice settings and across allied health ...
(Date:2/11/2016)... ... February 11, 2016 , ... "What holds you back from ... poses a question as a challenge for his readers to examine the full ... Being" (published by Partridge Singapore), Clarke explores the subject with more depth, revealing ...
(Date:2/11/2016)... ... 11, 2016 , ... PharmMD CEO Robert Yeager ... focus on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will ... in data breaches for the Part D Star Rating improvement and Medication Therapy ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Transformational M&A achieved through NPS and Dyax acquisitions ... Transformational M&A achieved through NPS and Dyax acquisitions and the ... M&A achieved through NPS and Dyax acquisitions and the announced ... with most robust pipeline in Shire , s ... most robust pipeline in Shire , s history ...
(Date:2/11/2016)... INDIANAPOLIS , Feb. 11, 2016 /PRNewswire/ ... people, but for those with type 1 diabetes, the ... students juggle class schedules, assignments and campus activities, they ... 1 diabetes. On top of that, many are living ... Diabetes Scholars Foundation (Foundation) Lilly Diabetes Tomorrow,s Leaders ...
(Date:2/11/2016)... LONDON , February 11, 2016 ... states that the Asia-Pacific (APAC) breast ... 2014 to $3.4 billion by 2021, at a Compound Annual ... Therapeutics in Asia-Pacific Markets to 2021 - states that ... will experience considerable expansion from $1.9 billion in 2014 to ...
Breaking Medicine Technology: